SCHEDULE: ADAR1 Capital Discloses 7.7% Stake in LeonaBio

ADAR1 Capital Management and Daniel Schneeberger have filed a Schedule 13G reporting a 7.7% beneficial ownership stake in LeonaBio, Inc.

Summary

• ADAR1 Capital Management, LLC and Daniel Schneeberger reported beneficial ownership of 727,481 shares of LeonaBio, Inc. common stock.
• The reported stake represents 7.7% of the company's outstanding common stock based on 9,393,514 shares outstanding as of March 31, 2026.
• The holdings are distributed across ADAR1 Partners, LP, Spearhead Insurance Solutions IDF, LLC, and other separately managed accounts.
• The filing excludes 1,230,315 shares underlying common warrants due to 4.99% beneficial ownership limitations.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a neutral, routine regulatory disclosure of existing institutional ownership.

Positives

• Institutional investment firm maintains a significant 7.7% position, signaling confidence in the issuer.
• The filing confirms the reporting persons are passive investors, as they certify the shares were not acquired to change or influence control of the issuer.

Negatives

• The reporting persons hold significant warrants (1,230,315 shares) that are currently restricted from exercise by a 4.99% beneficial ownership cap.

Risks

• The 4.99% beneficial ownership limitation on warrants may restrict the ability of the reporting persons to increase their equity position or exercise conversion rights in the near term.

Future Outlook

The reporting persons have certified that the securities were acquired in the ordinary course of business and not for the purpose of changing or influencing the control of the issuer.

Management Comments

• The reporting persons certify that the information set forth in the statement is true, complete, and correct.

Industry Context

StockSavvy.ai notes that this filing reflects standard institutional portfolio management activity within the small-cap biotechnology sector, where investment firms often utilize warrant structures with ownership caps to manage regulatory reporting requirements.

Comparison to Industry Standards

• The 7.7% stake is consistent with typical institutional holdings for small-cap biotech firms.
• The use of 4.99% ownership caps on warrants is a standard practice for institutional investors to avoid triggering early disclosure requirements or control-related regulatory hurdles.

Stakeholder Impact

• Shareholders may view the presence of an institutional investor with a 7.7% stake as a sign of stability.
• The existence of significant warrants may create potential future dilution if the 4.99% ownership cap is lifted or if the warrants are exercised.

Next Steps

• The reporting persons will continue to monitor their position in LeonaBio, Inc. in the ordinary course of business.

Key Dates

Keywords

LeonaBio, Schedule 13G, ADAR1 Capital, Institutional Ownership, Biotech, Equity Stake